Karolinska Development's portfolio company Umecrine Cognition includes first patient in Phase 2 study of golexanolon in primary biliary cholangitis

STOCKHOLM, SWEDEN – April 17, 2023. Karolinska Development AB today announces that its portfolio company Umecrine Cognition has included the first patient in a Phase 2 clinical trial of the... | April 17, 2023

Related Keywords

Stockholm ,Sweden ,Karolinska Institutet ,Viktor Drvota ,Johan Dighed ,Karolinska Development Ab Nasdaq Stockholm ,Karolinska Development ,Nasdaq Stockholm ,Umecrine Cognition ,General Counsel ,Karolinska Development Ab Publ Stock Exchange ,News ,Information ,Press Release ,Pril ,Karolinska ,Development ,Tb ,Oday ,Nnounces ,Hat ,Its ,Portfolio ,Company ,Mecrine ,Cognition ,Gas ,Ncluded ,The ,First ,Patient ,N ,Hase , ,Linical ,Trial ,F Kdev Se0002190926 ,